ArticleBMC surgery2026
Preoperative CT and inflammatory index-based risk scores for predicting short-term recurrence following resection of pancreatic ductal adenocarcinoma.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) carries a poor prognosis, with nearly half of resected patients relapsing within one year. Current National Comprehensive Cancer Network (NCCN) and American Joint Committee on Cancer (AJCC) staging systems inadequately reflect tumor biology. This study aimed to develop and validate preoperative risk scores integrating computed tomography (CT) features and systemic inflammatory markers to predict 12-month recurrence.
methodsIn this two-center retrospective cohort, consecutive patients with histologically confirmed resectable/borderline PDAC who underwent pancreaticoduodenectomy (2017-2024) were included. Standardized preoperative multiphase CT and laboratory data within 28 days before surgery were reviewed. Quantitative and qualitative CT parameters and inflammatory indices were analyzed using multiple imputation and pathway-specific logistic regression for up-front surgery (US) and neoadjuvant therapy (NT) groups. Model performance was evaluated by discrimination, calibration, and decision-curve analysis.
resultsOf 544 resections, 133 met eligibility (US = 81; NT = 52). Final models retained tumor size, necrosis, fat stranding, and the C-reactive protein-to-albumin ratio (CAR) and neutrophil-to-lymphocyte ratio (NLR) for US, and tumor size, hepatic-artery contact ≥ 90°, CAR, NLR, and carcinoembryonic antigen (CEA) for NT. Development area under the curve (AUC) values were 0.84 (US) and 0.81 (NT), and test AUCs were 0.82 and 0.78, respectively, outperforming AJCC 8ᵗʰ staging (ΔAUC + 0.19 and + 0.20).
conclusionsCompact, pathway-specific preoperative scores combining CT descriptors and inflammatory indices improved prediction of early recurrence compared with AJCC staging, supporting their potential use for individualized surgical and perioperative decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.